CBS 2019
CBSMD教育中心
English

Acute Coronary Syndrom

科研文章

荐读文献

MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS The year in cardiovascular medicine 2020: acute coronary syndromes and intensive cardiac care Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network) Decreased inspired oxygen stimulates de novo formation of coronary collaterals in adult heart Prognostic Significance of Complex Ventricular Arrhythmias Complicating ST-Segment Elevation Myocardial Infarction Symptom onset-to-balloon time and mortality in the first seven years after STEMI treated with primary percutaneous coronary intervention The Wait for High-Sensitivity Troponin Is Over—Proceed Cautiously Early Diagnosis of Myocardial Infarction With Point-of-Care High-Sensitivity Cardiac Troponin I Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
|<<... 8 9 10 11 12 13 14 ...>>|

Original Research2020 Jun 7;128:110336.

JOURNAL：Biomed Pharmacother. Article Link

Comparison of the Preventive Efficacy of Rosuvastatin Versus Atorvastatin in Post-Contrast Acute Kidney Injury in Patients With ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

YN Dai, JL Huang, DQ Yu et al. Keywords: atorvastatin; rosuvastatin; STEMI; PCI; post-contrast acute kidney injury

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top